Suzhou Changzheng-Xinkai Pharmaceutical

Suzhou Changzheng-Xinkai Pharmaceutical is a specialized pharmaceutical manufacturer based in Suzhou, China, primarily focused on the field of rheumatology and immunology. The company is a leading producer of Leflunomide, an immunosuppressive disease-modifying antirheumatic drug (DMARD) sold under the brand name Airuohua. Since its acquisition by China Grand Pharmaceutical and Healthcare Holdings, the company has integrated into a larger healthcare platform while maintaining its core expertise in small molecule production for autoimmune diseases. Its facilities are GMP-certified, supporting the large-scale commercialization of essential treatments for chronic inflammatory conditions. The company's products are widely used in the treatment of rheumatoid arthritis and lupus nephritis across China.